DelfaGLP-1 Atlas

Lead sponsor

Gan and Lee Pharmaceuticals, USA

10 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

10

Trials led

3

Active

1,250

Total enrollment

22

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
5
Phase 1/2
2
Phase 2
3

Trials by status

Not yet recruiting
2
Active, not recruiting
1
Completed
6
Unknown
1

Trials led

A Study of GZR18 Injection in Obese/Overweight PatientsBMI ≥28Ph 2Completed340
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsBMI ≥30Ph 2Not yet recruiting285
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes MellitusBMI ≥18.5Ph 2Unknown272
A Study of GZR18 Tablet in Chinese Healthy SubjectsBMI ≤24.9Ph 1Active, not recruiting92
A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)BMI 18.5-35Ph 1/2Completed72
A Study of GZR18 Injection in Chinese Obese/Overweight PatientsBMI ≥28Ph 1/2Completed60
A Phase I Study of GZR18 Injection in Healthy SubjectsBMI ≤26Ph 1Completed57
A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese SubjectsBMI 24-33Ph 1Not yet recruiting32
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy SubjectsBMI 20-35Ph 1Completed24
A Phase I Study of GZR18 Injection in Obese/Overweight SubjectsBMI ≥26Ph 1Completed16